SG11201502216UA - Cell lines - Google Patents

Cell lines

Info

Publication number
SG11201502216UA
SG11201502216UA SG11201502216UA SG11201502216UA SG11201502216UA SG 11201502216U A SG11201502216U A SG 11201502216UA SG 11201502216U A SG11201502216U A SG 11201502216UA SG 11201502216U A SG11201502216U A SG 11201502216UA SG 11201502216U A SG11201502216U A SG 11201502216UA
Authority
SG
Singapore
Prior art keywords
cell lines
lines
cell
Prior art date
Application number
SG11201502216UA
Other languages
English (en)
Inventor
Kenneth H Grabstein
Brunt Michael Van
Marcello Marelli
William Brady
Jeffrey Johnson
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11201502216UA publication Critical patent/SG11201502216UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/49Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/010251,4-Lactonase (3.1.1.25)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y601/00Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01Ligases forming aminoacyl-tRNA and related compounds (6.1.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201502216UA 2012-09-24 2013-09-24 Cell lines SG11201502216UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705116P 2012-09-24 2012-09-24
US201361862495P 2013-08-05 2013-08-05
PCT/EP2013/069887 WO2014044872A1 (en) 2012-09-24 2013-09-24 Cell lines

Publications (1)

Publication Number Publication Date
SG11201502216UA true SG11201502216UA (en) 2015-04-29

Family

ID=49237211

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502216UA SG11201502216UA (en) 2012-09-24 2013-09-24 Cell lines
SG10201702387YA SG10201702387YA (en) 2012-09-24 2013-09-24 Cell lines

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201702387YA SG10201702387YA (en) 2012-09-24 2013-09-24 Cell lines

Country Status (11)

Country Link
US (4) US9670521B2 (ja)
EP (2) EP2898085B1 (ja)
JP (2) JP6532404B2 (ja)
KR (1) KR102155389B1 (ja)
CN (2) CN104812734B (ja)
AU (1) AU2013320184B2 (ja)
BR (1) BR112015006368B1 (ja)
CA (1) CA2885796C (ja)
HK (2) HK1211569A1 (ja)
SG (2) SG11201502216UA (ja)
WO (2) WO2014044872A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655614B1 (en) 2010-12-22 2017-03-15 President and Fellows of Harvard College Continuous directed evolution
WO2013171485A1 (en) 2012-05-18 2013-11-21 Medical Research Council Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase.
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9670521B2 (en) 2012-09-24 2017-06-06 Medimmune Limited Amino acid derivatives
EP2970949B1 (en) 2013-03-15 2018-05-30 MedImmune Limited Novel nucleic acid molecules
ES2865473T3 (es) * 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3030545B1 (en) 2013-08-05 2020-10-07 MedImmune Limited Amino acid derivatives
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
GB2528227A (en) * 2014-03-14 2016-01-20 Medical Res Council Cyclopropene amino acids and methods
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
CN106146663B (zh) * 2015-04-10 2019-11-08 北京大学 非天然氨基酸标记的新型抗体-药物偶联物及其制备
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
JP6967221B2 (ja) * 2015-08-19 2021-11-17 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
CN107012121B (zh) * 2016-01-27 2021-01-26 北京大学 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建
EP3407917A1 (en) 2016-01-27 2018-12-05 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN105524167A (zh) * 2016-01-30 2016-04-27 深圳市贝沃德克生物技术研究院有限公司 抗乙肝e抗原的绿色荧光抗体的制备方法
CN105647918A (zh) * 2016-02-20 2016-06-08 深圳市圣必智科技开发有限公司 抗乙肝e抗原的红色荧光抗体的制备方法
SG11201811290VA (en) 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
US11214820B2 (en) * 2016-09-02 2022-01-04 Ikaria Inc. Functionally modified polypeptides and radiobiosynthesis
WO2018044143A1 (ko) * 2016-09-05 2018-03-08 한국과학기술원 목적 단백질의 위치 특이적 변형이 시공간적으로 조절되는 마우스, 이의 제조방법 및 그 용도
US10905107B2 (en) * 2016-09-05 2021-02-02 Korea Advanced Institute Of Science And Technology Transgenic mouse capable of spatial and temporal control of expression and site-specific modification of target protein, production method and uses thereof
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
WO2019010164A1 (en) * 2017-07-06 2019-01-10 President And Fellows Of Harvard College EVOLUTION OF ARNT SYNTHÉTASES
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019131964A1 (ja) 2017-12-27 2019-07-04 協和発酵キリン株式会社 Il-2改変体
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
CN110835633B (zh) * 2018-08-13 2021-10-01 北京大学 利用优化的基因密码子扩展系统制备ptc稳定细胞系及应用
JP2021536263A (ja) * 2018-09-07 2021-12-27 メディミューン,エルエルシー 細胞選択の方法
CN109553643B (zh) * 2018-11-29 2020-09-22 深圳先进技术研究院 单糖类似物及包含其的分子探针和该分子探针的应用
CN111850020B (zh) * 2019-04-25 2021-05-07 苏州鲲鹏生物技术有限公司 利用质粒系统在蛋白中引入非天然氨基酸
CN111909256A (zh) 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
CA3217226A1 (en) * 2021-04-21 2022-10-27 Asimov Inc. Stable production systems for adeno-associated virus production
EP4330214A2 (en) * 2021-04-28 2024-03-06 The Regents of the University of California Bioreactive proteins containing unnatural amino acids
KR20240024235A (ko) * 2021-07-29 2024-02-23 노보코덱스 바이오파마슈티컬즈 컴퍼니 리미티드 비천연 아미노산, 및 이의 용도, 이를 함유하는 재조합 단백질, 및 재조합 단백질 컨주게이트
EP4130254A1 (en) * 2021-08-03 2023-02-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Eukaryotic cell lysates comprising exogenous enzymes and methods for preparing the same
CN113698468B (zh) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其应用
CN113788890B (zh) * 2021-09-01 2022-11-08 浙江新码生物医药有限公司 一种人白细胞介素2-聚乙二醇偶联物及其应用
WO2023164676A1 (en) * 2022-02-27 2023-08-31 The Regents Of The University Of California Methods to generate novel acyl-trna species

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711458A (en) 1969-08-21 1973-01-16 Research Corp Substituted and unsubstituted vinyloxycarbonyl groups as amino protecting groups in the syntheses of peptides
US4512979A (en) 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
JPH0710451B2 (ja) 1986-11-25 1995-02-08 三五重機株式会社 鋼板カツタ−
HU207287B (en) 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
WO1991016449A1 (en) 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
EP2796546B1 (en) 2001-04-19 2017-08-09 The Scripps Research Institute Incorporation of unnatural amino acids
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
WO2004035605A2 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
US20040146941A1 (en) 2002-11-04 2004-07-29 Biliang Zhang Chemical encoding technology for combinatorial synthesis
AU2004233083B2 (en) * 2003-04-17 2010-09-16 The Scripps Research Institute Expanding the eukaryotic genetic code
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
JP2007037445A (ja) * 2005-08-02 2007-02-15 Institute Of Physical & Chemical Research tRNA合成方法、核酸、アミノアシルtRNA合成方法及び非天然型アミノ酸組み込み蛋白質の製造方法
CA2648009A1 (en) 2006-02-22 2007-09-07 Riken Method for synthesis of suppressor trna, dna construct, and production of protein having non-natural amino acid integrated therein by using the dna construct
EP2018437A2 (en) 2006-05-02 2009-01-28 Allozyne, Inc. Non-natural amino acid substituted polypeptides
AU2007333010A1 (en) * 2006-10-18 2008-06-19 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
BRPI0817212A2 (pt) 2007-09-20 2014-10-14 Riken Pirrolisil-trna sintetase mutante, e método para a produção de proteína tendo aminoácido não-natural integrado nela por sua utilização
EP2315922A1 (en) 2008-07-18 2011-05-04 Alantum Corporation Filter device for filtering automobile exhaust gas
US20100184134A1 (en) 2009-01-12 2010-07-22 Sutro Biopharma, Inc. Dual charging system for selectively introducing non-native amino acids into proteins using an in vitro synthesis method
WO2010083148A1 (en) 2009-01-13 2010-07-22 Sutro Biopharma, Inc. Use of dna gyrase inhibitors for in vitro polypeptide synthesis reactions
WO2010114615A2 (en) 2009-04-03 2010-10-07 The Scripps Research Institute A facile system for encoding unnatural amino acids in mammalian cells
GB2470770A (en) * 2009-06-04 2010-12-08 Medical Res Council Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs
WO2011044255A1 (en) 2009-10-06 2011-04-14 The Ohio State University Pyrrolysine analogs
CN107674121A (zh) * 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) * 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
EP2640745B1 (en) * 2010-09-10 2018-11-07 MedImmune Limited Bivalent and bispecific anti-il6/anti-il23 antibodies
DE102010041261A1 (de) 2010-09-23 2012-03-29 Robert Bosch Gmbh Flip-Chip Anordnung mit einem Kühlelement und Verfahren zur Herstellung einer Flip-Chip Anordnung
US20130183761A1 (en) 2010-09-24 2013-07-18 North Carolina State University Methods for Incorporating Unnatural Amino Acids in Eukaryotic Cells
CA2826041C (en) * 2011-02-03 2020-07-07 Embl Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
US9670521B2 (en) 2012-09-24 2017-06-06 Medimmune Limited Amino acid derivatives
EP2970949B1 (en) 2013-03-15 2018-05-30 MedImmune Limited Novel nucleic acid molecules

Also Published As

Publication number Publication date
EP2897935B1 (en) 2019-02-27
WO2014044873A1 (en) 2014-03-27
CN104812734A (zh) 2015-07-29
US20170306380A1 (en) 2017-10-26
JP6321658B2 (ja) 2018-05-09
US9670521B2 (en) 2017-06-06
JP2015530091A (ja) 2015-10-15
CN105026574B (zh) 2019-08-30
US10253345B2 (en) 2019-04-09
AU2013320184B2 (en) 2017-10-12
CN105026574A (zh) 2015-11-04
US9732367B2 (en) 2017-08-15
AU2013320184A1 (en) 2015-04-09
KR20150070186A (ko) 2015-06-24
EP2898085B1 (en) 2019-01-23
CA2885796A1 (en) 2014-03-27
HK1211569A1 (en) 2016-05-27
US20150251994A1 (en) 2015-09-10
BR112015006368A2 (ja) 2017-09-05
HK1211623A1 (en) 2016-05-27
KR102155389B1 (ko) 2020-09-11
US20150259721A1 (en) 2015-09-17
CA2885796C (en) 2022-05-03
US10214761B2 (en) 2019-02-26
SG10201702387YA (en) 2017-04-27
WO2014044872A1 (en) 2014-03-27
CN104812734B (zh) 2017-08-22
BR112015006368B1 (pt) 2022-02-08
EP2898085A1 (en) 2015-07-29
JP2015531789A (ja) 2015-11-05
JP6532404B2 (ja) 2019-06-19
EP2897935A1 (en) 2015-07-29
US20170306381A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
HK1211623A1 (en) Cell lines
DK3327112T3 (en) Agse-deficient stamme
ZA201503358B (en) Structure
EP2919313A4 (en) SOLID ELECTROLYTE
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
HK1209295A1 (en) Concentrator
AU347859S (en) Battery
AU346864S (en) Battery
EP2911230A4 (en) CELL
EP2824749A4 (en) BATTERY WITH A COATED STRUCTURE
EP2939306A4 (en) DRUMS
EP2831949A4 (en) SODIUM OXYGEN CELLS
GB201319035D0 (en) Spolier structure
EP2920142A4 (en) MÉTHANOFULLERRÈNES
IL239484A0 (en) Materials for omitting enterprise-tumor cells
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
EP2939294A4 (en) DRUMS
HUP1300640A2 (en) Belt-mounting structure
EP2863459A4 (en) FLAT CELL
EP2873363A4 (en) DIOPSIMETER
EP2871919A4 (en) STRUCTURE
GB201322593D0 (en) Push-scooter
EP2834250A4 (de) Lithiumsilikate
GB201218045D0 (en) Battery